Ranibizumab for Myopic Neovascularization

Exclusion Criteria

• •Patients with poor compliance
• •* Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (\< one year). (Physician clearance was obtained for all patients).
• •* Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.
• •* Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.
• •* Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.
• •* Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.
• •* Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.